New York State Common Retirement Fund boosted its holdings in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) by 337.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 23,981 shares of the company’s stock after buying an additional 18,500 shares during the quarter. New York State Common Retirement Fund owned 0.06% of Acumen Pharmaceuticals worth $94,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in ABOS. Deep Track Capital LP acquired a new stake in shares of Acumen Pharmaceuticals during the 4th quarter worth approximately $13,067,000. Woodline Partners LP grew its stake in shares of Acumen Pharmaceuticals by 2.5% during the 4th quarter. Woodline Partners LP now owns 480,681 shares of the company’s stock worth $3,249,000 after purchasing an additional 11,887 shares during the period. Strs Ohio grew its stake in shares of Acumen Pharmaceuticals by 24.0% during the 1st quarter. Strs Ohio now owns 41,300 shares of the company’s stock worth $161,000 after purchasing an additional 8,000 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Acumen Pharmaceuticals by 8.7% during the 4th quarter. Northern Trust Corp now owns 94,984 shares of the company’s stock worth $642,000 after purchasing an additional 7,583 shares during the period. Institutional investors and hedge funds own 64.42% of the company’s stock.
Acumen Pharmaceuticals Price Performance
Acumen Pharmaceuticals stock opened at $5.01 on Tuesday. The company’s fifty day moving average price is $5.04 and its 200 day moving average price is $4.70. Acumen Pharmaceuticals, Inc. has a 1 year low of $3.02 and a 1 year high of $19.46.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on ABOS. BTIG Research began coverage on shares of Acumen Pharmaceuticals in a research note on Friday, July 15th. They set a “buy” rating and a $15.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Acumen Pharmaceuticals in a research note on Tuesday, August 16th.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Receive News & Ratings for Acumen Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.